Search

Introduction: Due to COVID-19 restrictions, face-to-face educational meetings and conferences have either been delayed or cancelled. Continuing oncology professional education is vital and virtual platforms are increasingly being used to facilitate delivery. Methods: We organised a virtual meeting for Queensland oncologists, trainees and pharmaceutical representatives to share updates from the American Society of Clinical Oncology 2020 virtual meeting. The meeting was conducted on the Microsoft Teams™ platform on a Saturday as a single-day event, organised in eight separate 45-minute tumour-streamed presentations. An online feedback survey was sent to all attendees following the meeting. Results: A total of 96 participants attended the live meeting, which comprised report-back presenters, formal discussants, and concurrent sidebar chat interaction. Median number of active participants via chat feature per session was 13 (range, 8–18). Our survey had respondents, of whom 84% attended the live session. For future meetings, virtual delivery was the most favoured meeting format (by 45% responders), followed by face-to-face weekend event (31%) and dinner meeting (23%). The main perceived advantages reported of virtual delivery included: facilitation of remote attendance including from regional centres; the sidebar chat format which allowed concurrent, non-interruptive discussion by attendees; and the convenience of selective attendance of sessions of interest. The most common suggestions for improvement were related to meeting logistics: restructuring content delivery in the interests of time efficiency, and to enable recording for on-demand viewing. Conclusion: A virtual meeting platform proved to be convenient method for online oncology education. Based on the satisfaction rates and feedback, it will likely have an ongoing role in future meetings even after the COVID-19 pandemic.

Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains challenging, as contributing molecular pathways are poorly defined or expressed heterogeneously. CUB-domain containing protein 1 (CDCP1) is a cell-surface protein elevated in lung, colorectal, pancreas, renal and clear cell ovarian cancer.Methods: CUB-domain containing protein 1 was examined by immunohistochemistry in HGSC and fallopian tube. The impact of targeting CDCP1 on cell growth and migration in vitro, and intraperitoneal xenograft growth in mice was examined. Three patient-derived xenograft (PDX) mouse models were developed and characterised for CDCP1 expression. The effect of a monoclonal anti-CDCP1 antibody on PDX growth was examined. Src activation was assessed by western blot analysis.Results: Elevated CDCP1 was observed in 77% of HGSC cases. Silencing of CDCP1 reduced migration and non-adherent cell growth in vitro and tumour burden in vivo. Expression of CDCP1 in patient samples was maintained in PDX models. Antibody blockade of CDCP1 significantly reduced growth of an HGSC PDX. The CDCP1-mediated activation of Src was observed in cultured cells and mouse xenografts.Conclusions: CUB-domain containing protein 1 is over-expressed by the majority of HGSCs. In vitro and mouse model data indicate that CDCP1 has a role in HGSC and that it can be targeted to inhibit progression of this cancer.